Immunotherapy for Multiple Sclerosis
Summary Multiple sclerosis is the most common cause of non-traumatic neurological disability affecting young adults in the northern hemisphere. Recent technological advances in immunology, molecular biology and neuroimaging have accelerated our understanding of the pathogenesis of this disorder. Imp...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Kinkel, R. Philip [verfasserIn] Goodkin, Donald E. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1994 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: BioDrugs - Berlin [u.a.] : Springer, 1997, 1(1994), 2 vom: Feb., Seite 117-134 |
|---|---|
| Übergeordnetes Werk: |
volume:1 ; year:1994 ; number:2 ; month:02 ; pages:117-134 |
| Links: |
|---|
| DOI / URN: |
10.1007/BF03258498 |
|---|
| Katalog-ID: |
SPR032976682 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR032976682 | ||
| 003 | DE-627 | ||
| 005 | 20230519224639.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s1994 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/BF03258498 |2 doi | |
| 035 | |a (DE-627)SPR032976682 | ||
| 035 | |a (SPR)BF03258498-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Kinkel, R. Philip |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunotherapy for Multiple Sclerosis |
| 264 | 1 | |c 1994 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary Multiple sclerosis is the most common cause of non-traumatic neurological disability affecting young adults in the northern hemisphere. Recent technological advances in immunology, molecular biology and neuroimaging have accelerated our understanding of the pathogenesis of this disorder. Improvements in clinical trial methodology will soon allow researchers to test therapeutic agents in a fraction of the time traditionally required to study therapeutic claims in multiple sclerosis. The recent approval of interferon beta-1b by the US Food and Drug Administration has already had a profound effect on clinical trials in progress and on the manner in which neurologists in the US treat multiple sclerosis outside the confines of clinical trials. It will certainly be difficult to perform placebo-controlled clinical trials in the future. In light of these recent advances, we review the clinical experience of immunosuppressive and immunomodulatory therapies that have progressed beyond the pilot stage of testing. These therapies include azathioprine, copolymer I, corticosteroids, cyclophosphamide, cyclosporin, interferon-β, plasma exchange and total lymphoid irradiation. For each therapy a discussion of the potential mechanism of action is followed by a critical review of the pertinent clinical experience. Each section concludes with a commentary regarding the potential or proven risks and benefits of each therapy. | ||
| 650 | 4 | |a Multiple Sclerosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Multiple Sclerosis Patient |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Plasma Exchange |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Multiple Scle |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Serial Magnetic Resonance Imaging |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Goodkin, Donald E. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BioDrugs |d Berlin [u.a.] : Springer, 1997 |g 1(1994), 2 vom: Feb., Seite 117-134 |w (DE-627)327644672 |w (DE-600)2043743-2 |x 1179-190X |7 nnns |
| 773 | 1 | 8 | |g volume:1 |g year:1994 |g number:2 |g month:02 |g pages:117-134 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/BF03258498 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 951 | |a AR | ||
| 952 | |d 1 |j 1994 |e 2 |c 02 |h 117-134 | ||
| author_variant |
r p k rp rpk d e g de deg |
|---|---|
| matchkey_str |
article:1179190X:1994----::muohrpfrutpe |
| hierarchy_sort_str |
1994 |
| publishDate |
1994 |
| allfields |
10.1007/BF03258498 doi (DE-627)SPR032976682 (SPR)BF03258498-e DE-627 ger DE-627 rakwb eng 610 ASE Kinkel, R. Philip verfasserin aut Immunotherapy for Multiple Sclerosis 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Multiple sclerosis is the most common cause of non-traumatic neurological disability affecting young adults in the northern hemisphere. Recent technological advances in immunology, molecular biology and neuroimaging have accelerated our understanding of the pathogenesis of this disorder. Improvements in clinical trial methodology will soon allow researchers to test therapeutic agents in a fraction of the time traditionally required to study therapeutic claims in multiple sclerosis. The recent approval of interferon beta-1b by the US Food and Drug Administration has already had a profound effect on clinical trials in progress and on the manner in which neurologists in the US treat multiple sclerosis outside the confines of clinical trials. It will certainly be difficult to perform placebo-controlled clinical trials in the future. In light of these recent advances, we review the clinical experience of immunosuppressive and immunomodulatory therapies that have progressed beyond the pilot stage of testing. These therapies include azathioprine, copolymer I, corticosteroids, cyclophosphamide, cyclosporin, interferon-β, plasma exchange and total lymphoid irradiation. For each therapy a discussion of the potential mechanism of action is followed by a critical review of the pertinent clinical experience. Each section concludes with a commentary regarding the potential or proven risks and benefits of each therapy. Multiple Sclerosis (dpeaa)DE-He213 Multiple Sclerosis Patient (dpeaa)DE-He213 Plasma Exchange (dpeaa)DE-He213 Multiple Scle (dpeaa)DE-He213 Serial Magnetic Resonance Imaging (dpeaa)DE-He213 Goodkin, Donald E. verfasserin aut Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 1(1994), 2 vom: Feb., Seite 117-134 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:1 year:1994 number:2 month:02 pages:117-134 https://dx.doi.org/10.1007/BF03258498 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE AR 1 1994 2 02 117-134 |
| spelling |
10.1007/BF03258498 doi (DE-627)SPR032976682 (SPR)BF03258498-e DE-627 ger DE-627 rakwb eng 610 ASE Kinkel, R. Philip verfasserin aut Immunotherapy for Multiple Sclerosis 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Multiple sclerosis is the most common cause of non-traumatic neurological disability affecting young adults in the northern hemisphere. Recent technological advances in immunology, molecular biology and neuroimaging have accelerated our understanding of the pathogenesis of this disorder. Improvements in clinical trial methodology will soon allow researchers to test therapeutic agents in a fraction of the time traditionally required to study therapeutic claims in multiple sclerosis. The recent approval of interferon beta-1b by the US Food and Drug Administration has already had a profound effect on clinical trials in progress and on the manner in which neurologists in the US treat multiple sclerosis outside the confines of clinical trials. It will certainly be difficult to perform placebo-controlled clinical trials in the future. In light of these recent advances, we review the clinical experience of immunosuppressive and immunomodulatory therapies that have progressed beyond the pilot stage of testing. These therapies include azathioprine, copolymer I, corticosteroids, cyclophosphamide, cyclosporin, interferon-β, plasma exchange and total lymphoid irradiation. For each therapy a discussion of the potential mechanism of action is followed by a critical review of the pertinent clinical experience. Each section concludes with a commentary regarding the potential or proven risks and benefits of each therapy. Multiple Sclerosis (dpeaa)DE-He213 Multiple Sclerosis Patient (dpeaa)DE-He213 Plasma Exchange (dpeaa)DE-He213 Multiple Scle (dpeaa)DE-He213 Serial Magnetic Resonance Imaging (dpeaa)DE-He213 Goodkin, Donald E. verfasserin aut Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 1(1994), 2 vom: Feb., Seite 117-134 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:1 year:1994 number:2 month:02 pages:117-134 https://dx.doi.org/10.1007/BF03258498 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE AR 1 1994 2 02 117-134 |
| allfields_unstemmed |
10.1007/BF03258498 doi (DE-627)SPR032976682 (SPR)BF03258498-e DE-627 ger DE-627 rakwb eng 610 ASE Kinkel, R. Philip verfasserin aut Immunotherapy for Multiple Sclerosis 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Multiple sclerosis is the most common cause of non-traumatic neurological disability affecting young adults in the northern hemisphere. Recent technological advances in immunology, molecular biology and neuroimaging have accelerated our understanding of the pathogenesis of this disorder. Improvements in clinical trial methodology will soon allow researchers to test therapeutic agents in a fraction of the time traditionally required to study therapeutic claims in multiple sclerosis. The recent approval of interferon beta-1b by the US Food and Drug Administration has already had a profound effect on clinical trials in progress and on the manner in which neurologists in the US treat multiple sclerosis outside the confines of clinical trials. It will certainly be difficult to perform placebo-controlled clinical trials in the future. In light of these recent advances, we review the clinical experience of immunosuppressive and immunomodulatory therapies that have progressed beyond the pilot stage of testing. These therapies include azathioprine, copolymer I, corticosteroids, cyclophosphamide, cyclosporin, interferon-β, plasma exchange and total lymphoid irradiation. For each therapy a discussion of the potential mechanism of action is followed by a critical review of the pertinent clinical experience. Each section concludes with a commentary regarding the potential or proven risks and benefits of each therapy. Multiple Sclerosis (dpeaa)DE-He213 Multiple Sclerosis Patient (dpeaa)DE-He213 Plasma Exchange (dpeaa)DE-He213 Multiple Scle (dpeaa)DE-He213 Serial Magnetic Resonance Imaging (dpeaa)DE-He213 Goodkin, Donald E. verfasserin aut Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 1(1994), 2 vom: Feb., Seite 117-134 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:1 year:1994 number:2 month:02 pages:117-134 https://dx.doi.org/10.1007/BF03258498 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE AR 1 1994 2 02 117-134 |
| allfieldsGer |
10.1007/BF03258498 doi (DE-627)SPR032976682 (SPR)BF03258498-e DE-627 ger DE-627 rakwb eng 610 ASE Kinkel, R. Philip verfasserin aut Immunotherapy for Multiple Sclerosis 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Multiple sclerosis is the most common cause of non-traumatic neurological disability affecting young adults in the northern hemisphere. Recent technological advances in immunology, molecular biology and neuroimaging have accelerated our understanding of the pathogenesis of this disorder. Improvements in clinical trial methodology will soon allow researchers to test therapeutic agents in a fraction of the time traditionally required to study therapeutic claims in multiple sclerosis. The recent approval of interferon beta-1b by the US Food and Drug Administration has already had a profound effect on clinical trials in progress and on the manner in which neurologists in the US treat multiple sclerosis outside the confines of clinical trials. It will certainly be difficult to perform placebo-controlled clinical trials in the future. In light of these recent advances, we review the clinical experience of immunosuppressive and immunomodulatory therapies that have progressed beyond the pilot stage of testing. These therapies include azathioprine, copolymer I, corticosteroids, cyclophosphamide, cyclosporin, interferon-β, plasma exchange and total lymphoid irradiation. For each therapy a discussion of the potential mechanism of action is followed by a critical review of the pertinent clinical experience. Each section concludes with a commentary regarding the potential or proven risks and benefits of each therapy. Multiple Sclerosis (dpeaa)DE-He213 Multiple Sclerosis Patient (dpeaa)DE-He213 Plasma Exchange (dpeaa)DE-He213 Multiple Scle (dpeaa)DE-He213 Serial Magnetic Resonance Imaging (dpeaa)DE-He213 Goodkin, Donald E. verfasserin aut Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 1(1994), 2 vom: Feb., Seite 117-134 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:1 year:1994 number:2 month:02 pages:117-134 https://dx.doi.org/10.1007/BF03258498 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE AR 1 1994 2 02 117-134 |
| allfieldsSound |
10.1007/BF03258498 doi (DE-627)SPR032976682 (SPR)BF03258498-e DE-627 ger DE-627 rakwb eng 610 ASE Kinkel, R. Philip verfasserin aut Immunotherapy for Multiple Sclerosis 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Multiple sclerosis is the most common cause of non-traumatic neurological disability affecting young adults in the northern hemisphere. Recent technological advances in immunology, molecular biology and neuroimaging have accelerated our understanding of the pathogenesis of this disorder. Improvements in clinical trial methodology will soon allow researchers to test therapeutic agents in a fraction of the time traditionally required to study therapeutic claims in multiple sclerosis. The recent approval of interferon beta-1b by the US Food and Drug Administration has already had a profound effect on clinical trials in progress and on the manner in which neurologists in the US treat multiple sclerosis outside the confines of clinical trials. It will certainly be difficult to perform placebo-controlled clinical trials in the future. In light of these recent advances, we review the clinical experience of immunosuppressive and immunomodulatory therapies that have progressed beyond the pilot stage of testing. These therapies include azathioprine, copolymer I, corticosteroids, cyclophosphamide, cyclosporin, interferon-β, plasma exchange and total lymphoid irradiation. For each therapy a discussion of the potential mechanism of action is followed by a critical review of the pertinent clinical experience. Each section concludes with a commentary regarding the potential or proven risks and benefits of each therapy. Multiple Sclerosis (dpeaa)DE-He213 Multiple Sclerosis Patient (dpeaa)DE-He213 Plasma Exchange (dpeaa)DE-He213 Multiple Scle (dpeaa)DE-He213 Serial Magnetic Resonance Imaging (dpeaa)DE-He213 Goodkin, Donald E. verfasserin aut Enthalten in BioDrugs Berlin [u.a.] : Springer, 1997 1(1994), 2 vom: Feb., Seite 117-134 (DE-627)327644672 (DE-600)2043743-2 1179-190X nnns volume:1 year:1994 number:2 month:02 pages:117-134 https://dx.doi.org/10.1007/BF03258498 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE AR 1 1994 2 02 117-134 |
| language |
English |
| source |
Enthalten in BioDrugs 1(1994), 2 vom: Feb., Seite 117-134 volume:1 year:1994 number:2 month:02 pages:117-134 |
| sourceStr |
Enthalten in BioDrugs 1(1994), 2 vom: Feb., Seite 117-134 volume:1 year:1994 number:2 month:02 pages:117-134 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Multiple Sclerosis Multiple Sclerosis Patient Plasma Exchange Multiple Scle Serial Magnetic Resonance Imaging |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
BioDrugs |
| authorswithroles_txt_mv |
Kinkel, R. Philip @@aut@@ Goodkin, Donald E. @@aut@@ |
| publishDateDaySort_date |
1994-02-01T00:00:00Z |
| hierarchy_top_id |
327644672 |
| dewey-sort |
3610 |
| id |
SPR032976682 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032976682</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519224639.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1994 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03258498</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032976682</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03258498-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kinkel, R. Philip</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunotherapy for Multiple Sclerosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1994</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Multiple sclerosis is the most common cause of non-traumatic neurological disability affecting young adults in the northern hemisphere. Recent technological advances in immunology, molecular biology and neuroimaging have accelerated our understanding of the pathogenesis of this disorder. Improvements in clinical trial methodology will soon allow researchers to test therapeutic agents in a fraction of the time traditionally required to study therapeutic claims in multiple sclerosis. The recent approval of interferon beta-1b by the US Food and Drug Administration has already had a profound effect on clinical trials in progress and on the manner in which neurologists in the US treat multiple sclerosis outside the confines of clinical trials. It will certainly be difficult to perform placebo-controlled clinical trials in the future. In light of these recent advances, we review the clinical experience of immunosuppressive and immunomodulatory therapies that have progressed beyond the pilot stage of testing. These therapies include azathioprine, copolymer I, corticosteroids, cyclophosphamide, cyclosporin, interferon-β, plasma exchange and total lymphoid irradiation. For each therapy a discussion of the potential mechanism of action is followed by a critical review of the pertinent clinical experience. Each section concludes with a commentary regarding the potential or proven risks and benefits of each therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple Sclerosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple Sclerosis Patient</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Plasma Exchange</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple Scle</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Serial Magnetic Resonance Imaging</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goodkin, Donald E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BioDrugs</subfield><subfield code="d">Berlin [u.a.] : Springer, 1997</subfield><subfield code="g">1(1994), 2 vom: Feb., Seite 117-134</subfield><subfield code="w">(DE-627)327644672</subfield><subfield code="w">(DE-600)2043743-2</subfield><subfield code="x">1179-190X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:1994</subfield><subfield code="g">number:2</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:117-134</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03258498</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">1994</subfield><subfield code="e">2</subfield><subfield code="c">02</subfield><subfield code="h">117-134</subfield></datafield></record></collection>
|
| author |
Kinkel, R. Philip |
| spellingShingle |
Kinkel, R. Philip ddc 610 misc Multiple Sclerosis misc Multiple Sclerosis Patient misc Plasma Exchange misc Multiple Scle misc Serial Magnetic Resonance Imaging Immunotherapy for Multiple Sclerosis |
| authorStr |
Kinkel, R. Philip |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)327644672 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1179-190X |
| topic_title |
610 ASE Immunotherapy for Multiple Sclerosis Multiple Sclerosis (dpeaa)DE-He213 Multiple Sclerosis Patient (dpeaa)DE-He213 Plasma Exchange (dpeaa)DE-He213 Multiple Scle (dpeaa)DE-He213 Serial Magnetic Resonance Imaging (dpeaa)DE-He213 |
| topic |
ddc 610 misc Multiple Sclerosis misc Multiple Sclerosis Patient misc Plasma Exchange misc Multiple Scle misc Serial Magnetic Resonance Imaging |
| topic_unstemmed |
ddc 610 misc Multiple Sclerosis misc Multiple Sclerosis Patient misc Plasma Exchange misc Multiple Scle misc Serial Magnetic Resonance Imaging |
| topic_browse |
ddc 610 misc Multiple Sclerosis misc Multiple Sclerosis Patient misc Plasma Exchange misc Multiple Scle misc Serial Magnetic Resonance Imaging |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
BioDrugs |
| hierarchy_parent_id |
327644672 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
BioDrugs |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)327644672 (DE-600)2043743-2 |
| title |
Immunotherapy for Multiple Sclerosis |
| ctrlnum |
(DE-627)SPR032976682 (SPR)BF03258498-e |
| title_full |
Immunotherapy for Multiple Sclerosis |
| author_sort |
Kinkel, R. Philip |
| journal |
BioDrugs |
| journalStr |
BioDrugs |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
1994 |
| contenttype_str_mv |
txt |
| container_start_page |
117 |
| author_browse |
Kinkel, R. Philip Goodkin, Donald E. |
| container_volume |
1 |
| class |
610 ASE |
| format_se |
Elektronische Aufsätze |
| author-letter |
Kinkel, R. Philip |
| doi_str_mv |
10.1007/BF03258498 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
immunotherapy for multiple sclerosis |
| title_auth |
Immunotherapy for Multiple Sclerosis |
| abstract |
Summary Multiple sclerosis is the most common cause of non-traumatic neurological disability affecting young adults in the northern hemisphere. Recent technological advances in immunology, molecular biology and neuroimaging have accelerated our understanding of the pathogenesis of this disorder. Improvements in clinical trial methodology will soon allow researchers to test therapeutic agents in a fraction of the time traditionally required to study therapeutic claims in multiple sclerosis. The recent approval of interferon beta-1b by the US Food and Drug Administration has already had a profound effect on clinical trials in progress and on the manner in which neurologists in the US treat multiple sclerosis outside the confines of clinical trials. It will certainly be difficult to perform placebo-controlled clinical trials in the future. In light of these recent advances, we review the clinical experience of immunosuppressive and immunomodulatory therapies that have progressed beyond the pilot stage of testing. These therapies include azathioprine, copolymer I, corticosteroids, cyclophosphamide, cyclosporin, interferon-β, plasma exchange and total lymphoid irradiation. For each therapy a discussion of the potential mechanism of action is followed by a critical review of the pertinent clinical experience. Each section concludes with a commentary regarding the potential or proven risks and benefits of each therapy. |
| abstractGer |
Summary Multiple sclerosis is the most common cause of non-traumatic neurological disability affecting young adults in the northern hemisphere. Recent technological advances in immunology, molecular biology and neuroimaging have accelerated our understanding of the pathogenesis of this disorder. Improvements in clinical trial methodology will soon allow researchers to test therapeutic agents in a fraction of the time traditionally required to study therapeutic claims in multiple sclerosis. The recent approval of interferon beta-1b by the US Food and Drug Administration has already had a profound effect on clinical trials in progress and on the manner in which neurologists in the US treat multiple sclerosis outside the confines of clinical trials. It will certainly be difficult to perform placebo-controlled clinical trials in the future. In light of these recent advances, we review the clinical experience of immunosuppressive and immunomodulatory therapies that have progressed beyond the pilot stage of testing. These therapies include azathioprine, copolymer I, corticosteroids, cyclophosphamide, cyclosporin, interferon-β, plasma exchange and total lymphoid irradiation. For each therapy a discussion of the potential mechanism of action is followed by a critical review of the pertinent clinical experience. Each section concludes with a commentary regarding the potential or proven risks and benefits of each therapy. |
| abstract_unstemmed |
Summary Multiple sclerosis is the most common cause of non-traumatic neurological disability affecting young adults in the northern hemisphere. Recent technological advances in immunology, molecular biology and neuroimaging have accelerated our understanding of the pathogenesis of this disorder. Improvements in clinical trial methodology will soon allow researchers to test therapeutic agents in a fraction of the time traditionally required to study therapeutic claims in multiple sclerosis. The recent approval of interferon beta-1b by the US Food and Drug Administration has already had a profound effect on clinical trials in progress and on the manner in which neurologists in the US treat multiple sclerosis outside the confines of clinical trials. It will certainly be difficult to perform placebo-controlled clinical trials in the future. In light of these recent advances, we review the clinical experience of immunosuppressive and immunomodulatory therapies that have progressed beyond the pilot stage of testing. These therapies include azathioprine, copolymer I, corticosteroids, cyclophosphamide, cyclosporin, interferon-β, plasma exchange and total lymphoid irradiation. For each therapy a discussion of the potential mechanism of action is followed by a critical review of the pertinent clinical experience. Each section concludes with a commentary regarding the potential or proven risks and benefits of each therapy. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE |
| container_issue |
2 |
| title_short |
Immunotherapy for Multiple Sclerosis |
| url |
https://dx.doi.org/10.1007/BF03258498 |
| remote_bool |
true |
| author2 |
Goodkin, Donald E. |
| author2Str |
Goodkin, Donald E. |
| ppnlink |
327644672 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/BF03258498 |
| up_date |
2024-07-03T15:49:43.988Z |
| _version_ |
1803573562170146816 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032976682</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519224639.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1994 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03258498</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032976682</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03258498-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kinkel, R. Philip</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunotherapy for Multiple Sclerosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1994</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Multiple sclerosis is the most common cause of non-traumatic neurological disability affecting young adults in the northern hemisphere. Recent technological advances in immunology, molecular biology and neuroimaging have accelerated our understanding of the pathogenesis of this disorder. Improvements in clinical trial methodology will soon allow researchers to test therapeutic agents in a fraction of the time traditionally required to study therapeutic claims in multiple sclerosis. The recent approval of interferon beta-1b by the US Food and Drug Administration has already had a profound effect on clinical trials in progress and on the manner in which neurologists in the US treat multiple sclerosis outside the confines of clinical trials. It will certainly be difficult to perform placebo-controlled clinical trials in the future. In light of these recent advances, we review the clinical experience of immunosuppressive and immunomodulatory therapies that have progressed beyond the pilot stage of testing. These therapies include azathioprine, copolymer I, corticosteroids, cyclophosphamide, cyclosporin, interferon-β, plasma exchange and total lymphoid irradiation. For each therapy a discussion of the potential mechanism of action is followed by a critical review of the pertinent clinical experience. Each section concludes with a commentary regarding the potential or proven risks and benefits of each therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple Sclerosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple Sclerosis Patient</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Plasma Exchange</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple Scle</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Serial Magnetic Resonance Imaging</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goodkin, Donald E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BioDrugs</subfield><subfield code="d">Berlin [u.a.] : Springer, 1997</subfield><subfield code="g">1(1994), 2 vom: Feb., Seite 117-134</subfield><subfield code="w">(DE-627)327644672</subfield><subfield code="w">(DE-600)2043743-2</subfield><subfield code="x">1179-190X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:1994</subfield><subfield code="g">number:2</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:117-134</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03258498</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">1994</subfield><subfield code="e">2</subfield><subfield code="c">02</subfield><subfield code="h">117-134</subfield></datafield></record></collection>
|
| score |
7.400732 |